Saturday 17 October 2026
Export ELV’s income statement to Excel — free account
Elevance Health, Inc.
ELV Healthcare Healthcare Plans
Elevance Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $199.1 billion, up 12.5% from fiscal 2024. In the quarter to June 2026, revenue grew 1.40%, EPS fell 13.1%, free cash flow fell 9.01% and total debt rose 4.08%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.
428.26
0.17
−0.04%
Follow ELV
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
13.21 | 13.96 | 12.45 | 17.19 |
P/S ratio |
0.37 | 0.39 | 0.32 | 0.42 | |
P/FCF ratio |
19.15 | 24.74 | 9.98 | 13.34 | |
P/Operating CF |
63.57 | 934.80 | 14.85 | 43.87 | |
P/B ratio |
1.64 | 1.78 | 1.46 | 1.86 | |
Price to Tangible BV |
16.76 | 17.52 | 13.96 | 14.72 | |
EV/Sales |
0.35 | 0.37 | 0.29 | 0.39 | |
EV/EBITDA |
6.78 | 7.69 | 6.38 | 8.79 | |
EV/Operating CF |
13.81 | 17.32 | 7.68 | 10.38 | |
EV/FCF |
18.01 | 23.41 | 9.05 | 12.32 | |
Quick Ratio |
1.43 | 1.41 | 1.32 | 1.38 | |
Current Ratio |
1.56 | 1.54 | 1.48 | 1.52 | |
Net Debt/EBITDA |
(2.00) | (4.27) | (1.98) | (2.43) | |
Debt/Assets |
26.01% | 26.25% | 24.73% | 24.55% | |
Debt/Equity |
0.72 | 0.72 | 0.71 | 0.69 | |
Asset Turnover |
1.63 | 1.67 | 1.63 | 1.62 | |
Operating CF/Net income |
0.95 | 0.15 | 2.46 | 1.31 | |
Capex/Depreciation |
(0.93) | (0.72) | (0.66) | (0.78) | |
Interest Coverage |
5.01 | 1.59 | 7.45 | 6.32 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.32 | 0.33 | 0.31 | 0.31 | |
Share Based Compensation of Revenue |
0.17% | 0.06% | 0.11% | 0.15% | |
Graham Net Nets |
(0.21) | (0.18) | (0.23) | (0.17) | |
Graham Number |
329.61 | 333.30 | 325.56 | 324.09 | |
Earnings Yield |
7.57% | 7.17% | 8.03% | 5.82% | |
Free Cash Flow Yield |
5.22% | 4.04% | 10.02% | 7.49% | |
Revenue per Share |
227.10 | 222.08 | 228.30 | 232.60 | |
Operating CF per Share |
5.08 | 0.38 | 19.71 | 8.82 | |
Capex per Share |
(1.61) | (1.31) | (1.07) | (1.32) | |
Free Cash Flow per Share |
3.47 | (0.93) | 18.64 | 7.49 | |
Cash per Share |
162.19 | 161.23 | 168.67 | 172.88 | |
Shareholders Equity per Share |
197.41 | 196.54 | 200.37 | 207.47 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
197.41 | 196.54 | 200.37 | 207.47 | |
Free Cash Flow |
775.00 | (209.00) | 4,097.00 | 1,626.00 | |
Working Capital |
22,900.00 | 21,966.00 | 21,723.00 | 22,930.00 | |
Capital Expenditures |
(360.00) | (293.00) | (235.00) | (287.00) | |
Net Current Asset Value |
(14,889.00) | (14,467.00) | (14,753.00) | (14,232.00) | |
EV/EBIT |
8.01 | 9.16 | 7.65 | 10.61 | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.01 | |
Price to Operating Income |
8.51 | 9.68 | 8.43 | 11.50 | |
| Other line items | |||||
Average Receivables |
20,374.00 | 20,306.50 | 22,485.50 | 23,258.50 | |
Average Payables |
22,417.00 | 23,539.50 | 24,288.50 | 24,764.00 | |
Average Assets |
119,641.00 | 119,191.50 | 122,772.00 | 124,188.00 | |
Average Common Equity |
43,980.50 | 42,726.00 | 43,331.00 | 44,436.50 |
Columns are period end dates